|Harvard Medical School, M.D.||1993|
|Yale University, BS||1988|
Dr. Multani is the chief medical officer at Fate Therapeutics.
Prior to joining Fate Therapeutics, Dr. Multani had been vice president of translational medicine at Kalypsys, Inc. since 2007, where he advanced the development of multiple compounds in the therapeutic areas of pain and inflammation and metabolic diseases.
From 2005 to 2007 as senior vice president of clinical development and then chief medical officer at Kanisa Pharmaceuticals, Dr. Multani led the clinical development of zosuquidar as well as a companion diagnostic for the treatment of acute myeloid leukemia.
From 2004 to 2005 as vice president of clinical development at Salmedix, he led three clinical development programs in hematologic malignancies and solid tumors.
From 1999 to 2004 advancing from associate director of oncology and hematology to senior director of medical research at Biogen-Idec, Dr. Multani led or provided strategic direction for multiple drug development programs from pre-IND to Phase 4 clinical trials, including Zevalin® and Rituxan.
Pratik received his undergraduate degree from Yale University, his MD from Harvard Medical School and received post-doctoral training in epidemiology at the Harvard School of Public Health.
He completed his Internal Medicine residency at the Massachusetts General Hospital followed by a medical oncology fellowship at the Dana Farber/Partners joint program, after which he was a member of the transplant unit at Massachusetts General Hospital.